Alembic Pharmaceuticals has achieved another regulatory milestone with the US FDA granting final approval for its supplemental Abbreviated New Drug Application (sANDA) for Paroxetine Extended-Release Tablets USP, 12.5 mg. This approval marks a significant addition to the company's growing portfolio of generic pharmaceutical products in the United States market.

FDA Approval Details

The newly approved Paroxetine Extended-Release tablets are therapeutically equivalent to the reference listed drug product (RLD), Paxil CR Tablets, 12.5 mg, of Apotex Inc. This approval demonstrates Alembic Pharmaceuticals' capability to develop and manufacture complex generic formulations that meet stringent FDA standards.

Therapeutic Applications

Paroxetine extended-release tablets are indicated for the treatment of multiple conditions including Major depressive disorder (MDD), Panic disorder (PD), Social anxiety disorder (SAD), and Premenstrual dysphoric disorder (PMDD). This broad therapeutic scope positions the product as a valuable addition to Alembic's central nervous system portfolio.

Expanding US Portfolio

With this latest approval, Alembic Pharmaceuticals has now accumulated a cumulative total of 235 US ANDA approvals, comprising 216 final approvals and 19 tentative approvals. This substantial portfolio reflects the company's consistent efforts in developing generic alternatives to branded medications, providing more affordable treatment options for patients in the American healthcare system.

Strategic Significance

The approval of Paroxetine Extended-Release tablets adds to Alembic Pharmaceuticals' therapeutic offerings in the central nervous system segment. Extended-release formulations require sophisticated manufacturing capabilities and regulatory expertise, highlighting the company's technical competencies in pharmaceutical development and production at its state-of-the-art facilities approved by regulatory authorities including the USFDA.

Alembic Pharmaceuticals Limited has announced a scheduled one-on-one investor meeting with Nomura Holdings, demonstrating the company's commitment to maintaining regular dialogue with institutional investors and stakeholders.

Meeting Details

The pharmaceutical company has provided specific details about the upcoming investor engagement:

Regulatory Compliance

The company has fulfilled its regulatory obligations by notifying both major stock exchanges about this investor meeting. The intimation was filed on March 20, 2026, under Regulation 30, which governs disclosure requirements for listed companies.

The notification was simultaneously sent to:

• BSE Limited (Scrip Code: 533573)
• National Stock Exchange of India Ltd. (Symbol: APLLTD)

Corporate Communication

Company Secretary Manisha Saraf signed the official communication, ensuring proper authorization and documentation of the investor engagement activity. The digital signature was applied on March 20, 2026, at 11:36:25 IST, providing a clear audit trail for the regulatory filing.

Such investor meetings are part of standard corporate practices, allowing institutional investors to engage directly with company management and gain insights into business operations, strategic direction, and financial performance. The video conferencing format reflects modern communication practices while maintaining effective investor relations.